Bioprocessing Reimagined
Isolere Bio delivers manufacturing solutions that accelerate therapeutic development, harmonize commercial scaling, and improve global access to life changing medicines and vaccines.
Isolere Bio was founded in 2017 with the vision of re-imagining the manufacturing of biologics. Donaldson, with its own vision for bringing its history of filtration innovation to the life sciences industry, saw our value and acquired the company in 2023. We are now part of a portfolio of solutions addressing major biomanufacturing bottlenecks with novel, scalable solutions and close partnership with our customers.
Our Mission
Accelerate the development of therapeutics to improve human health and global accessibility
We develop bioprocesses that improve product quality, reduce waste, and scale linearly. Isolere Bio is committed to bringing life-changing therapies to patients around the globe more quickly and more affordably.
Our Niche
Develop and deliver reagents and accompanying processes that streamline manufacturing
We innovate in the bioprocessing space by bringing all available technologies together in a highly cross-functional environment to streamline the production of biologics.
The newly defined Donaldson Life Sciences division is building a portfolio of biopharma innovations to provide cutting-edge technologies that simplify and accelerate development and production of therapeutics.
We are leveraging Donaldson’s over 100-year legacy as a global leader in filtration solutions and customer-centric service. We solve the world's most complex filtration challenges, and now are working to revolutionize solutions for biopharmaceutical applications.
Our strategy is underpinned by developing critical filtration, purification, and separation technologies that service the discovery, development, and GMP production of biopharmaceuticals. Isolere Bio, Purilogics, Solaris Biotech, and Univercells Technologies work together to provide differentiated solutions for advanced therapeutic bioprocessing, while also consolidating multiple steps in the bioprocessing value-chain. We work with you, innovate, and deliver.
Isolere Bio
We are our people.
The Isolere Bio Leadership Team
Kelli Luginbuhl
-
Kelli received her PhD in Biomedical Engineering from Duke University where she studied the design and development of phase separating proteins for various biomedical applications. She co-founded Isolere Bio in 2018 with the mission of reimagining the way the industry approaches advanced therapeutics manufacturing.
Initially serving as Chief Scientific Officer, Kelli is an inventor on many of Isolere’s core patents. She transitioned into the CEO role in 2019 and helped secure a $7M seed round in 2021. She continues to lead the Isolere team in the role of General Manager, reporting to the President of Life Sciences after the acquisition and integration into Donaldson Company in 2023. The company is focused on the launch, scale up, and commercialization of first of its kind purification reagents for AAV, LV, and ssRNA.
Michael Dzuricky
-
Mike attended Duke University to earn his PhD in Biomedical Engineering, publishing over 20 co-authored research papers and filing 2 patents during his tenure.
After taking over as Chief Scientific Officer at Isolere Bio in 2019, Mike has been responsible for the technological development of Isolere Bio core products, responsible for growing the research and operations department from 3 to over 20 employees and submitting numerous successful grant applications to various funding agencies, including NIH and BARDA.
Now, a Director of R&D with Donaldson Company, Mike is focused on expanding the pipeline of the Donaldson Life Science business and bringing innovations from concept to prototype.
Shameer Subratty
-
Shameer joined Isolere Bio in 2022, bringing over nine years of experience in R&D and Product Management focused on developing novel purification technologies that enhance productivity and reduce costs of biotherapeutic manufacturing.
His career includes significant contributions at Cytiva, GE Healthcare, and Puridify, where he played a pivotal role in positioning the Fibro technology for acquisition by GE Healthcare in 2017. Shameer's expertise in leading start-ups through successful acquisitions and integrations was invaluable as Isolere Bio embarked on a similar journey with Donaldson in 2023.
Shameer holds a Master’s in Engineering from Queen Mary University of London and is an inventor on four patents for membrane chromatography consumables and equipment.
Kimberly Anderson
-
Kimberly received her PhD in Marine Estuarine Environmental Sciences from the University of Maryland College Park, where she specialized in microbiology and biotechnology. She has 15 years of experience in developing and scaling biologically-based processes from bench scale to production scale. Her experience includes fermentation optimization as well as downstream purification process optimization for commercialization of products in food, personal care, energy, advance materials, and pharmaceutical industries.
As Director of Commercial R&D at Isolere, Kim is responsible for leading products from prototype to commercial launch at higher grades and larger scale of more regular batch production.
Life Science Technical Center
Isolere Bio is located in an Alexandria Center in Research Triangle Park (RTP), a hub where many biotechnology and cell and gene therapy companies come together. This close proximity allows for collaboration, learning, and conferences between scientists. The campus hosts a number of benefits, including fitness amenities, an on-site restaurant and bar, and paved nature trails leading throughout RTP.
Located between Durham, Raleigh, Chapel Hill, and Cary, our 24,000 sq ft facility features cutting edge equipment allowing for the research, process and application development, and manufacturing of recombinant proteins. The facility comes equipped with 6 laboratory spaces and an ISO 7 capable clean room environment in our 6,000 sq ft manufacturing suite. We are currently in the process of becoming ISO 9001 certified as we move into launching new and enabling bioprocessing reagents.
Integrity. Inclusion. Innovation.
Pride in our people and a passion for what we’re building together.
At Isolere, we want to foster a meritocratic workplace where the best ideas win and mutual respect is non-negotiable. Regularly scheduled social and volunteering events are prioritized to build close working relationships outside the lab and office, as well as to better our local community. Come join a team of innovative, kindhearted people that believe in Isolere’s founding mission of accelerating and improving global access to life changing medicines.